Biotech | March 14, 2026
MetaVia locks down global patent shield for metabolic drug candidate Vanoglipel
The protections extend through at least 2035, with the potential for further extensions
The protections extend through at least 2035, with the potential for further extensions
The Japan Patent Office is considered one of the world's most rigorous and meticulous in its review process
The initiative will focus on creating healthier early-life environments, promoting physical activity, identifying risks early, and strengthening preparedness within primary health care systems
Marks significant milestone for breakthrough biologic to treat rare blood cancers
Launches advanced bone density systems in India & Dubai
The trial met its primary endpoint, with patients receiving povetacicept achieving a 52.0% reduction in UPCR at Week 36
Diasens and GlucoLive are designed for diabetic, Chronic Kidney Disease (CKD), and post-transplant patients who require continuous glycaemic surveillance and integrated remote care
The Hydrus Microstent stands out as the first and only MIGS device backed by five-year clinical outcomes
The study hit its primary goal, showing a statistically significant rise in participants achieving EASI-75
The hospitals house over 25 super-speciality centres and Centres of Excellence in Cardiology, Neurology, Oncology, Paediatrics, Orthopaedics, ENT, Obstetrics and Gynaecology, General Surgery, Internal Medicine, Critical Care, and Chronic Disease Management
Subscribe To Our Newsletter & Stay Updated
